title: Ureaplasma, bronchopulmonary dysplasia, and azithromycin in European neonatal intensive care units: a survey.
abstract: A survey was set up to gauge the opinions of neonatologists on the role of Ureaplasma in bronchopulmonary dysplasia (BPD) development, the use of azithromycin for BPD prevention, and the factors influencing azithromycin use in European neonatal intensive care units (NICUs). 167 NICUs participated in the survey, representing 28 European countries. For respondents, the two major perceived risk factors for BPD were prematurity of <28 weeks and high oxygen requirements. Only 38% of NICUs had a protocol for BPD prevention and 47% routinely tested for Ureaplasma. In cases of infection, macrolides were the first choice. Most (78%) NICUs were interested in participating in a trial evaluating azithromycin safety and efficacy in reducing BPD rates. Opinions and clinical practice varied between European neonatal units, and differences in Ureaplasma treatment and prevention of BPD highlight the need for further azithromycin evaluation and for improved therapeutic knowledge in preterms.
authors: Department of Public Health, Laboratory for Mother and Child Health, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Via G. La Masa 19, 20156, Milan, Italy.
authors: Claudia
authors: C
authors: Pansieri
authors: Department of Public Health, Laboratory for Mother and Child Health, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Via G. La Masa 19, 20156, Milan, Italy.
authors: Chiara
authors: C
authors: Pandolfini
authors: Service de Pharmacologie Pédiatrique, AP-HP, Hôpital Robert Debré, 48 boulevard Serurier, 75019 Paris, France.
authors: Valery
authors: V
authors: Elie
authors: Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool Women's Hospital, Crown Street, Liverpool L8 7SS, UK.
authors: Mark A
authors: MA
authors: Turner
authors: Department of Child Health, Cardiff University School of Medicine, Cardiff CF14 4XN, UK.
authors: Sailesh
authors: S
authors: Kotecha
authors: Service de Pharmacologie Pédiatrique, AP-HP, Hôpital Robert Debré, 48 boulevard Serurier, 75019 Paris, France.
authors: Evelyne
authors: E
authors: Jacqz-Aigrain
authors: Department of Public Health, Laboratory for Mother and Child Health, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Via G. La Masa 19, 20156, Milan, Italy.
authors: Maurizio
authors: M
authors: Bonati
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017963:Azithromycin / Q000494:pharmacology* / Q000627:therapeutic use; D001997:Bronchopulmonary Dysplasia / Q000209:etiology*; D003625:Data Collection; D005060:Europe; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007363:Intensive Care Units, Neonatal; D012307:Risk Factors; D011795:Surveys and Questionnaires; D014509:Ureaplasma / Q000187:drug effects*; D016869:Ureaplasma Infections / Q000517:prevention & control
chemical_list: D000900:Anti-Bacterial Agents; D017963:Azithromycin